BioCryst Pharmaceuticals Inc (STU:BO1)
€ 7.244 0.082 (1.14%) Market Cap: 1.52 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

BioCryst Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 12:00PM GMT
Release Date Price: €7.66 (-3.01%)
Brian Abrahams
RBC Capital Markets - Moderator

Welcome to day two of RBC's Annual Healthcare Conference. I'm Brian Abrahams, one of the senior biotech analysts here. Really pleased to have our first company this morning, BioCryst Pharmaceuticals, represented by their President and CEO, Jon Stonehouse. Jon, thanks so much for joining us.

Jon Stonehouse
BioCryst Pharmaceuticals, Inc. - President, CEO

Yeah, thanks for having us.

Questions & Answers

Brian Abrahams
RBC Capital Markets - Moderator

Great. So I wanted to start big picture on the HAE market. Can you tell us a little bit more about what you've learned since the Orladeyo launch about what the treatment paradigm and market dynamics look like here? I guess I'm curious if there are still HAE patients out there who may not yet be plugged into an allergist or maybe who are engaged with a specialist but are not on prophylactic therapy. What you guys are doing to identify patients, help them switch off of existing medications, and also help them engage

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot